[ad_1]
CoronaVac, developed by the Chinese Sinovac Biotech, showed effectiveness between 50% and 90% in Brazilian tests, said the Secretary of Health of the State of São Paulo after the The government of São Paulo postpones on Wednesday (23), for the third time, the publication of data on the vaccine.
The results of the tests are known exclusively to the Butantan Institute’s biomedical research center, which has an agreement with Sinovac for the production of the vaccine, Health Secretary Jean Gorinchteyn said.
The first trials showed effectiveness above 50%, the minimum required by Anvisa, and below 90%, Gorinchteyn said in a radio interview. CBN Issued on Thursday night (24).
On Wednesday, Butantan declined to specify the effectiveness rate of a trial with 13,000 volunteers, citing its contractual obligations to Sinovac, raising questions about the transparency of those working with the vaccine.
A CoronaVac showed 91.25% effectiveness in Turkey, according to an announcement on Thursday (24) of provisional data for a final stage test in the country.
Copyright © Thomson Reuters.
